Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Fluzoparib +/- Adebrelimab in TP53-mutant NSCLC
NCT05932264Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib, fluzoparib, adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
Rivoceranibfluzoparibadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05932264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932264.